u/Dan-Exigent

I’m hoping to hear from others with Stage IV stomach/gastric cancer who are being treated with FOLFOX + nivolumab.

I just finished treatment #4, and my first CT showed what appears to be a mixed response. Some of my lymph nodes have gotten smaller or remained stable, but the liver lesions did not show the response we were hoping for and appear to have progressed.

Has anyone here had a similar experience where:

* Lymph nodes responded, but disease in an organ such as the liver did not initially respond?
* Your first scan after only a few treatments showed little improvement or even a mixed response, but later scans became more favorable?
* Your oncologist continued FOLFOX + nivolumab despite an early mixed response, and you eventually saw better disease control or shrinkage?

I realize everyone’s cancer behaves differently, and I’m not looking to compare prognoses or replace my oncologist’s guidance. I’m mainly interested in hearing real-world experiences from people who were not clear responders on their first scan but went on to have a better response later.

Again, I’ve only completed four treatments, so I’m especially interested in anyone whose first restaging scan came this early in treatment.

Thank you to anyone willing to share their experience. It would mean a lot.

I’m hoping to hear from others with Stage IV stomach/gastric cancer who are being treated with FOLFOX + nivolumab.
I just finished treatment #4, and my first CT showed what appears to be a mixed response. Some of my lymph nodes have gotten smaller or remained stable, but the liver lesions did not show the response we were hoping for and appear to have progressed.
Has anyone here had a similar experience where:
Lymph nodes responded, but disease in an organ such as the liver did not initially respond?
Your first scan after only a few treatments showed little improvement or even a mixed response, but later scans became more favorable?
Your oncologist continued FOLFOX + nivolumab despite an early mixed response, and you eventually saw better disease control or shrinkage?
I realize everyone’s cancer behaves differently, and I’m not looking to compare prognoses or replace my oncologist’s guidance. I’m mainly interested in hearing real-world experiences from people who were not clear responders on their first scan but went on to have a better response later.
Again, I’ve only completed four treatments, so I’m especially interested in anyone whose first restaging scan came this early in treatment.
Thank you to anyone willing to share their experience. It would mean a lot.

I was looking at SoundHound (SOUN) versus the S&P 500 and found this comparison pretty eye-opening.

At roughly a 25.8x P/E, buying the S&P 500 through SPY means you’re paying about:
$25.82 for every $1 of actual earnings.
SOUN can’t even be evaluated the same way because it currently has negative earnings. There is no positive $1 of profit to attach a P/E multiple to.

So instead, look at revenue.
At roughly a $3.3B market cap and around $245M in projected 2026 revenue, SOUN investors are paying roughly:
$13 for every $1 of revenue.
Not earnings. Revenue.

Here’s another way to look at it.
Let’s assume SOUN eventually achieves a very healthy 20% net profit margin.
$245M revenue × 20% = about $49M in earnings.

At a $3.3B valuation, that would effectively mean investors are paying roughly:
$67 for every $1 of earnings.

So:
SPY: ~$26 for every $1 of actual earnings
SOUN today: No positive earnings
SOUN at a hypothetical 20% net margin: ~$67 for every $1 of earnings

That doesn’t necessarily mean SOUN is a bad investment. Revenue is growing rapidly, and if SoundHound eventually gets to $750M, $1B+ in annual revenue while expanding margins, today’s valuation could ultimately look reasonable—or even cheap.
But it does illustrate what you’re actually betting on.

With SPY you’re buying existing earnings.
With SOUN you’re paying a significant premium for earnings you hope will exist several years from now.

For the SOUN bulls: What revenue and net-margin assumptions are you using to justify the current valuation?

Looking for anyone who has had conflicting PET/CT and MRI findings involving the liver during a cancer workup.

I was recently diagnosed with gastric adenocarcinoma. My initial PET/CT and subsequent CT scan raised concern for possible liver metastases. The reports described several small liver lesions that were considered suspicious, although not definitively diagnostic.

I then underwent an MRI with contrast, and the MRI report described the liver findings as multiple simple hepatic cysts, with no obvious features suggesting metastatic disease. The MRI report did not characterize the lesions as suspicious.
At the same time, enlarged lymph nodes have been identified in several locations, including retroperitoneal and thoracic regions, which continue to be concerning for metastatic involvement.
As you can imagine, this has left me in a confusing situation:

PET/CT and CT suggesting possible liver metastases.
MRI suggesting benign liver cysts.
Lymph node findings that still appear suspicious.
My oncologists are now pursuing tissue diagnosis to determine exactly what is going on.

Has anyone here experienced:
PET/CT findings that looked metastatic but MRI suggested benign cysts?

Liver lesions that turned out not to be cancer despite concerning imaging?
Conflicting interpretations between PET, CT, and MRI that were only resolved by biopsy?
If so, what was the final outcome?

I’m especially interested in hearing from gastric cancer patients, but experiences from any cancer type would be helpful.

This waiting period between scans and biopsy results is proving to be one of the most difficult parts of the process.

Thank you for sharing your experiences .

TL;DR

Looking for others with Stage IV HER2-negative, CLDN18.2-positive gastric cancer receiving zolbetuximab

Hello everyone,
I’m a 55-year-old male who was recently diagnosed with gastric adenocarcinoma and am looking to connect with others who have a similar diagnosis and treatment plan.

My pathology and staging information so far:
Gastric adenocarcinoma
HER2 negative (IHC 2+, FISH negative)
CLDN18.2 positive (~80%)
PD-L1 CPS score: 2
pMMR (microsatellite stable)
PET/CT showed suspected liver metastases and distant lymph node involvement

Liver MRI is underway for further evaluation
Care is being transferred to Memorial Sloan Kettering
The current treatment plan is expected to include:
FOLFOX chemotherapy
Zolbetuximab (Vyloy)

I’m particularly hoping to hear from people who:
Have CLDN18.2-positive disease
Have received zolbetuximab
Had liver metastases at diagnosis
Achieved a major response, remission, or NED
Have been living with metastatic gastric cancer for several years.

I’d love to hear about:
How difficult treatment was
Side effects from zolbetuximab and FOLFOX
How quickly your scans showed a response
Whether your liver lesions shrank significantly

Any advice for someone just starting this journey
I realize everyone’s cancer is different, but hearing from people with a similar biomarker profile would be incredibly helpful right now.

Thank you, and I wish everyone here the very best in their fight.